Generics sign patent pool pledge to improve access to COVID-19 treatments

17-11-2020

Muireann Bolger

Generics sign patent pool pledge to improve access to COVID-19 treatments

Blue Planet Studio / Shutterstock.com

In response to the surge of COVID-19 infections worldwide, 18 generic drug makers have pledged to join the effort by the Medicines Patent Pool (MPP) to accelerate global access to effective COVID-19 treatments via a pool for voluntary product licences.


Adcock Ingram, Arene Life Sciences, Aurobindo, Beximco, Celltrion, Desano, Hetero, Lupin, Langua Pharma, Macleods, Mangalam Drugs & Drugs, Micro Labs

LSIPR